Capital Flow Monitor · Sponsors · CIK 890821
Enveric Biosciences, Inc.
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142 · (617) 444-8400
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$5.0M
Sold
$5.0M
% sold
100.0%
Investors
4
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | D ·current | 506(b) | $5.0M | $5.0M | 100.0% | 4 | EDGAR ↗ |
| 2026-02-11 | D | 506(b) | $1.5M | $1.5M | 100.0% | 5 | EDGAR ↗ |
| 2025-12-23 | D | 506(b) | $107K | $107K | 100.0% | 15 | EDGAR ↗ |
| 2025-10-03 | D | 506(b) | — | $0 | — | 12 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed.
- Joseph E. Tucker — Executive Officer / Director, Cambridge, MA
- Kevin M. Coveney — Executive Officer, Cambridge, MA
- Michael D. Webb — Director, Cambridge, MA
- George W. Kegler — Director, Cambridge, MA
- Michael Schabacker — Director, Cambridge, MA
- Frank Pasqualone — Director, Cambridge, MA
- Sheila DeWitt — Director, Cambridge, MA
Placement agents
- H.c. Wainwright & Co., Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.